A case of paliperidone-palmitate-induced tardive dyskinesia

General Hospital Psychiatry

Volumn 35, Issue 2, 2013, Pages 213.e5-213.e7

  Lally, John ^a,b   Byrne, Fintan ^b   Walsh, Elizabeth ^b  

^a NATIONAL UNIVERSITY OF IRELAND   (Ireland)

^b HEALTH SERVICE EXECUTIVE   (Ireland)

Author keywords

Long acting; Paliperidone; Paranoid schizophrenia; Second generation antipsychotics; Tardive dyskinesia

Indexed keywords

CLONAZEPAM; LONG ACTING DRUG; OLANZAPINE; PALIPERIDONE; RISPERIDONE;

ADULT; ARTICLE; CASE REPORT; DISEASE SEVERITY; DRUG RESPONSE; DRUG WITHDRAWAL; FEMALE; HOSPITALIZATION; HUMAN; MAINTENANCE DRUG DOSE; PARANOID SCHIZOPHRENIA; PATIENT COMPLIANCE; TARDIVE DYSKINESIA;

EID: 84875363929     PISSN: 01638343     EISSN: 18737714     Source Type: Journal    
DOI: 10.1016/j.genhosppsych.2012.04.009     Document Type: Article

References (22)

1. Margolese H.C., Chouinard G., Kolivakis T.T., Beauclair L., Miller R., Annable L. Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 2: incidence and management strategies in patients with schizophrenia. Can J Psychiatry 2005, 50:703-714.
2. Tarsy D., Baldessarini R.J. Tardive dyskinesia. Annu Rev Med 1984, 35:605-623.
3. Kapur S., Seeman P. Does fast dissociation from the dopamine d (2) receptor explain the action of atypical antipsychotics? A new hypothesis. Am J Psychiatry 2001, 158:360-369.
4. Gerlach J., Reisby N., Randrup A. Dopaminergic hypersensitivity and cholinergic hypofunction in the pathophysiology of tardive dyskinesia. Psychopharm. 1974, 34:21-35.
5. Soares K.V., McGrath J.J., Deeks J.J. Gamma-aminobutyric acid agonists for neuroleptic-induced tardive dyskinesia. Cochrane Database Sys Rev 2000, (2):CD000205. Review.
6. Miller R., Chouinard G. Loss of striatal cholinergic neurons as a basis for tardive dyskinesia and L-dopa-induced dyskinesias, neuroleptic-induced supersensitivity psychosis and refractory schizophrenia. Biol Psychiatry 1993, 34:713-738.
7. Soares K.V., McGrath J.J. The treatment of tardive dyskinesia-systematic review and meta-analysis. Schizophr Res 1999, 39:1-16.
8. American Psychiatric Association Tardive dyskinesia: a task force report of the American Psychiatric Association. Hosp Community Psychiatry 1993, 44:190.
9. Beasley C., Dellva M.A., Tamura R.N., Morgenstern H., Glazer W.M., Ferguson K., et al. Randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol. Br J Psychiatry 1999, 174:23-30.
10. Cu C., Leucht S., Kane J.M. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1 year studies. Am J Psychiatry 2004, 161:414-425.
11. Correll C.U., Schenk E.M. Tardive dyskinesia and new antipsychotics. Curr Opin Psychiatry 2008, 21:151-156.
12. Canuso C.M., Battisti W.P. Paliperidone extended-release: a review of efficacy and tolerability in schizophrenia, schizoaffective disorder and bipolar mania. Expert Opin Pharmacother 2010, 11:2557-2567.
13. Nasrallah H.A., Gopal S., Gassmann-Mayer C., Quiroz J.A., Lim P., Eerdekens M., et al. A controlled, evidence-based trial of paliperidone palmitate, a long-acting injectable antipsychotic, in schizophrenia. Neuropsychopharmacology 2010, 35:2072-2082.
14. Hough D., Gopal S., Vijapurkar U., Lim P., Morozova M., Eerdekens M. Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. Schizophr Res 2010, 116:107-117.
15. Abnormal Involuntary Movement Scale (AIMS). Psychopharmacol Bull 1988, 24(4):781-783.
16. Schooler N.R., Kane J.M. Research diagnoses for tardive dyskinesia. Arch Gen Psychiatry 1982, 39:486-487.
17. Gopal S., Berwaerts J., Nuamah I., Akhras K., Coppola D., Daly E., et al. Number needed to treat and number needed to harm with paliperidone palmitate relative to long-acting haloperidol, bromperidol, and fluphenazine decanoate for treatment of patients with schizophrenia. Neuropsychiatr Dis Treat. 2011, 7:93-101.
18. Hough D, Gopal S, Vijapurkar U, Lim P, Morozova M, Eerdekens M. Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: A randomized, double-blind, placebo-controlled study. Schizophr Res. 116; 17-117.
19. Han-Ting W., Ya-Wen L., Mu-Hong C., Ying-Sheue C. Oral-paliperidone-induced tardive dyskinesia: a case report. Gen Hosp Psychiatry 2011, epub.
20. Teng P.R., Lai T.J. Paliperidone-related rabbit syndrome. J Clin Psychopharmacol 2011, 31:379-380.
21. Kinon B.J., Jeste D.V., Kollack-Walker S., Stauffer V., Liu-Seifert H. Olanzapine treatment for tardive dyskinesia in schizophrenia patients: a prospective clinical trial with patients randomised to blinded dose reduction periods. Prog Neuropsychopharmacol Biol Psych 2004, 985-996.
22. Soutullo C.A., Keck P.E., McElroy S.L. Olanzapine in the treatment of tardive dyskinesia: a report of two cases. J Clin Psychopharmacol 1999, 19:100-101.